1
|
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares‐Lupon N, Schmit K, Le Reste P, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E. Dual IRE1 RNase functions dictate glioblastoma development. EMBO Mol Med 2023; 15:e16731. [PMID: 36752056 PMCID: PMC9906329 DOI: 10.15252/emmm.202216731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 12/06/2022] [Indexed: 02/09/2023] Open
|
2
|
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares-Lupon N, Schmit K, Le Reste PJ, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E. Dual IRE1 RNase functions dictate glioblastoma development. EMBO Mol Med 2022; 14:e15622. [PMID: 35014200 DOI: 10.15252/emmm.202115622] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 11/09/2022] Open
|
3
|
Le Reste PJ, Pineau R, Voutetakis K, Samal J, Jégou G, Lhomond S, Gorman AM, Samali A, Patterson JB, Zeng Q, Pandit A, Aubry M, Soriano N, Etcheverry A, Chatziioannou A, Mosser J, Avril T, Chevet E. Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo. Cancer Lett 2020; 494:73-83. [PMID: 32882336 DOI: 10.1016/j.canlet.2020.08.028] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 08/11/2020] [Accepted: 08/20/2020] [Indexed: 01/07/2023]
Abstract
Glioblastoma multiforme (GBM) is the most severe primary brain cancer. Despite an aggressive treatment comprising surgical resection and radio/chemotherapy, patient's survival post diagnosis remains short. A limitation for success in finding novel improved therapeutic options for such dismal disease partly lies in the lack of a relevant animal model that accurately recapitulates patient disease and standard of care. In the present study, we have developed an immunocompetent GBM model that includes tumor surgery and a radio/chemotherapy regimen resembling the Stupp protocol and we have used this model to test the impact of the pharmacological inhibition of the endoplasmic reticulum (ER) stress sensor IRE1, on treatment efficacy.
Collapse
Affiliation(s)
- Pierre Jean Le Reste
- Inserm U1242, University of Rennes, Rennes, France; Centre de lutte contre le cancer Eugène Marquis, Rennes, France; Rennes Brain Cancer Team (REACT), 35000, Rennes, France; Neurosurgery Dept, University Hospital of Rennes, 35000, Rennes, France
| | - Raphael Pineau
- Inserm U1242, University of Rennes, Rennes, France; Centre de lutte contre le cancer Eugène Marquis, Rennes, France; Rennes Brain Cancer Team (REACT), 35000, Rennes, France
| | - Konstantinos Voutetakis
- Institute of Chemical Biology, National Hellenic Research Foundation (N.H.R.F.), Athens, Greece; Department of Biochemistry and Biotechnology, University of Thessaly, Viopolis, 41500, Larissa, Greece
| | - Juhi Samal
- CÚRAM, Centre for Research in Medical Devices, National University of Ireland, Galway, Ireland
| | - Gwénaële Jégou
- Inserm U1242, University of Rennes, Rennes, France; Centre de lutte contre le cancer Eugène Marquis, Rennes, France; Rennes Brain Cancer Team (REACT), 35000, Rennes, France
| | - Stéphanie Lhomond
- CÚRAM, Centre for Research in Medical Devices, National University of Ireland, Galway, Ireland; Apoptosis Research Centre, National University Ireland Galway, Galway, Ireland
| | - Adrienne M Gorman
- CÚRAM, Centre for Research in Medical Devices, National University of Ireland, Galway, Ireland; Apoptosis Research Centre, National University Ireland Galway, Galway, Ireland
| | - Afshin Samali
- Apoptosis Research Centre, National University Ireland Galway, Galway, Ireland
| | - John B Patterson
- Fosun OrinovePharmaTech Inc., 3537 Old Conejo Road, Suite 104, Newbury Park, CA, 91320, USA
| | - Qingping Zeng
- Fosun OrinovePharmaTech Inc., 3537 Old Conejo Road, Suite 104, Newbury Park, CA, 91320, USA
| | - Abhay Pandit
- CÚRAM, Centre for Research in Medical Devices, National University of Ireland, Galway, Ireland
| | - Marc Aubry
- Rennes Brain Cancer Team (REACT), 35000, Rennes, France; University of Rennes, CNRS, IGDR [(Institut de Génétique et développement de Rennes)]-UMR 6290, F-35000, Rennes, France; CHU Rennes, Service de Génétique Moléculaire et Génomique Médicale, Rennes, France
| | - Nicolas Soriano
- Rennes Brain Cancer Team (REACT), 35000, Rennes, France; University of Rennes, CNRS, IGDR [(Institut de Génétique et développement de Rennes)]-UMR 6290, F-35000, Rennes, France
| | - Amandine Etcheverry
- CHU Rennes, Service de Génétique Moléculaire et Génomique Médicale, Rennes, France
| | - Aristotelis Chatziioannou
- Institute of Chemical Biology, National Hellenic Research Foundation (N.H.R.F.), Athens, Greece; e-NIOS PC, Kallithea-Athens, Greece
| | - Jean Mosser
- Rennes Brain Cancer Team (REACT), 35000, Rennes, France; University of Rennes, CNRS, IGDR [(Institut de Génétique et développement de Rennes)]-UMR 6290, F-35000, Rennes, France; CHU Rennes, Service de Génétique Moléculaire et Génomique Médicale, Rennes, France; University of Rennes, Plateforme GEH, CNRS, Inserm, BIOSIT - UMS 3480, US_S 018, F-35000, Rennes, France
| | - Tony Avril
- Inserm U1242, University of Rennes, Rennes, France; Centre de lutte contre le cancer Eugène Marquis, Rennes, France; Rennes Brain Cancer Team (REACT), 35000, Rennes, France
| | - Eric Chevet
- Inserm U1242, University of Rennes, Rennes, France; Centre de lutte contre le cancer Eugène Marquis, Rennes, France; Rennes Brain Cancer Team (REACT), 35000, Rennes, France.
| |
Collapse
|
4
|
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares‐Lupon N, Schmit K, Le Reste P, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E. Dual IRE1 RNase functions dictate glioblastoma development. EMBO Mol Med 2018; 10:emmm.201707929. [PMID: 29311133 PMCID: PMC5840541 DOI: 10.15252/emmm.201707929] [Citation(s) in RCA: 111] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Proteostasis imbalance is emerging as a major hallmark of cancer, driving tumor aggressiveness. Evidence suggests that the endoplasmic reticulum (ER), a major site for protein folding and quality control, plays a critical role in cancer development. This concept is valid in glioblastoma multiform (GBM), the most lethal primary brain cancer with no effective treatment. We previously demonstrated that the ER stress sensor IRE1α (referred to as IRE1) contributes to GBM progression, through XBP1 mRNA splicing and regulated IRE1-dependent decay (RIDD) of RNA Here, we first demonstrated IRE1 signaling significance to human GBM and defined specific IRE1-dependent gene expression signatures that were confronted to human GBM transcriptomes. This approach allowed us to demonstrate the antagonistic roles of XBP1 mRNA splicing and RIDD on tumor outcomes, mainly through selective remodeling of the tumor stroma. This study provides the first demonstration of a dual role of IRE1 downstream signaling in cancer and opens a new therapeutic window to abrogate tumor progression.
Collapse
Affiliation(s)
| | - Tony Avril
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | | | - Konstantinos Voutetakis
- Institute of Biology, Medicinal Chemistry & BiotechnologyNHRFAthensGreece,Department of Biochemistry & BiotechnologyUniversity of ThessalyLarissaGreece
| | - Dimitrios Doultsinos
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Mari McMahon
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance,Apoptosis Research CentreSchool of Natural SciencesNUI GalwayGalwayIreland
| | - Raphaël Pineau
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Joanna Obacz
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Olga Papadodima
- Institute of Biology, Medicinal Chemistry & BiotechnologyNHRFAthensGreece
| | - Florence Jouan
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Heloise Bourien
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Marianthi Logotheti
- Institute of Biology, Medicinal Chemistry & BiotechnologyNHRFAthensGreece,e‐NIOS PCKallithea‐AthensGreece
| | - Gwénaële Jégou
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | | | | | - Pierre‐Jean Le Reste
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Department of NeurosurgeryUniversity Hospital PontchaillouRennesFrance
| | - Amandine Etcheverry
- Integrated Functional Genomics and Biomarkers TeamUMR6290, CNRSUniversité de Rennes 1RennesFrance
| | - Jean Mosser
- Integrated Functional Genomics and Biomarkers TeamUMR6290, CNRSUniversité de Rennes 1RennesFrance
| | - Kim Barroso
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Elodie Vauléon
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Marion Maurel
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance,Apoptosis Research CentreSchool of Natural SciencesNUI GalwayGalwayIreland
| | - Afshin Samali
- Apoptosis Research CentreSchool of Natural SciencesNUI GalwayGalwayIreland
| | | | - Olivier Pluquet
- Institut Pasteur de LilleCNRS UMR8161 “Mechanisms of Tumourigenesis and Targeted Therapies”Université de LilleLilleFrance
| | - Claudio Hetz
- Biomedical Neuroscience InstituteFaculty of MedicineUniversity of ChileSantiagoChile,Program of Cellular and Molecular BiologyInstitute of Biomedical SciencesUniversity of ChileSantiagoChile,Center for Geroscience, Brain Health and MetabolismSantiagoChile,Buck Institute for Research on AgingNovatoCAUSA,Department of Immunology and Infectious diseasesHarvard School of Public HealthBostonMAUSA
| | - Véronique Quillien
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| | - Aristotelis Chatziioannou
- Institute of Biology, Medicinal Chemistry & BiotechnologyNHRFAthensGreece,e‐NIOS PCKallithea‐AthensGreece
| | - Eric Chevet
- INSERM U1242, “Chemistry, Oncogenesis, Stress, Signaling”Université de Rennes 1RennesFrance,Centre de Lutte Contre le Cancer Eugène MarquisRennesFrance
| |
Collapse
|
5
|
Doultsinos D, Avril T, Lhomond S, Dejeans N, Guédat P, Chevet E. Control of the Unfolded Protein Response in Health and Disease. SLAS Discov 2017; 22:787-800. [PMID: 28453376 DOI: 10.1177/2472555217701685] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The unfolded protein response (UPR) is an integrated, adaptive biochemical process that is inextricably linked with cell homeostasis and paramount to maintenance of normal physiological function. Prolonged accumulation of improperly folded proteins in the endoplasmic reticulum (ER) leads to stress. This is the driving stimulus behind the UPR. As such, prolonged ER stress can push the UPR past beneficial functions such as reduced protein production and increased folding and clearance to apoptotic signaling. The UPR is thus contributory to the commencement, maintenance, and exacerbation of a multitude of disease states, making it an attractive global target to tackle conditions sorely in need of novel therapeutic intervention. The accumulation of information of screening tools, readily available therapies, and potential pathways to drug development is the cornerstone of informed clinical research and clinical trial design. Here, we review the UPR's involvement in health and disease and, beyond providing an in-depth description of the molecules found to target the three UPR arms, we compile all the tools available to screen for and develop novel therapeutic agents that modulate the UPR with the scope of future disease intervention.
Collapse
Affiliation(s)
- Dimitrios Doultsinos
- 1 Inserm U1242, Chemistry, Oncogenesis, Stress & Signaling, University of Rennes 1, Rennes, France.,2 Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France
| | - Tony Avril
- 1 Inserm U1242, Chemistry, Oncogenesis, Stress & Signaling, University of Rennes 1, Rennes, France.,2 Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France
| | | | | | | | - Eric Chevet
- 1 Inserm U1242, Chemistry, Oncogenesis, Stress & Signaling, University of Rennes 1, Rennes, France.,2 Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France.,3 BMYscreen, Bergonié Cancer Institute, Bordeaux, France
| |
Collapse
|
6
|
Jabouille A, Delugin M, Pineau R, Dubrac A, Soulet F, Lhomond S, Pallares-Lupon N, Prats H, Bikfalvi A, Chevet E, Touriol C, Moenner M. Glioblastoma invasion and cooption depend on IRE1α endoribonuclease activity. Oncotarget 2016; 6:24922-34. [PMID: 26325176 PMCID: PMC4694804 DOI: 10.18632/oncotarget.4679] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 07/10/2015] [Indexed: 12/19/2022] Open
Abstract
IRE1α is an endoplasmic reticulum (ER)-resident transmembrane signaling protein and a cellular stress sensor. The protein harbors a cytosolic dual kinase/endoribonuclease activity required for adaptive responses to micro-environmental changes. In an orthotopic xenograft model of human glioma, invalidation of IRE1α RNase or/and kinase activities generated tumors with remarkably distinct phenotypes. Contrasting with the extensive angiogenesis observed in tumors derived from control cells, the double kinase/RNase invalidation reprogrammed mesenchymal differentiation of cancer cells and produced avascular and infiltrative glioblastomas with blood vessel co-option. In comparison, selective invalidation of IRE1α RNase did not compromise tumor angiogenesis but still elicited invasive features and vessel co-option. In vitro, IRE1α RNase deficient cells were also endowed with a higher ability to migrate. Constitutive activation of both enzymes led to wild-type-like lesions. The presence of IRE1α, but not its RNase activity, is therefore required for glioblastoma neovascularization, whereas invasion results only from RNase inhibition. In this model, two key mechanisms of tumor progression and cancer cell survival are functionally linked to IRE1α.
Collapse
Affiliation(s)
- Arnaud Jabouille
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | - Maylis Delugin
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | | | | | - Fabienne Soulet
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | - Stéphanie Lhomond
- Université de Bordeaux, 33000 Bordeaux, France.,Inserm, U1053, 33000 Bordeaux, France
| | - Nestor Pallares-Lupon
- Université de Bordeaux, 33000 Bordeaux, France.,Inserm, U1053, 33000 Bordeaux, France
| | - Hervé Prats
- Inserm, U1037, CHU de Rangueil, 31432 Toulouse, France
| | - Andreas Bikfalvi
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | - Eric Chevet
- Université de Bordeaux, 33000 Bordeaux, France.,Inserm, U1053, 33000 Bordeaux, France.,Centre Régional de Lutte Contre le Cancer Eugène Marquis, 35000 Rennes, France.,ER440, Oncogenesis, Stress, Signaling, Université Rennes 1, Rennes, France
| | | | - Michel Moenner
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France.,CNRS UMR5095, IBGC, 33700 Bordeaux, France
| |
Collapse
|
7
|
Lhomond S, Pallares N, Barroso K, Schmit K, Dejeans N, Fazli H, Taouji S, Patterson JB, Chevet E. Adaptation of the secretory pathway in cancer through IRE1 signaling. Methods Mol Biol 2015; 1292:177-94. [PMID: 25804756 DOI: 10.1007/978-1-4939-2522-3_13] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The unfolded protein response (UPR) was originally identified as a signaling network coordinating adaptive and apoptotic responses to accumulation of unfolded proteins in the endoplasmic reticulum (ER). More recent work has shown that UPR signaling can be triggered by a multitude of cellular events and that the UPR plays a critical role in the prevention of cell transformation but also in tumor development. This has been particularly well illustrated with studies on one of the three major ER stress sensors, IRE1. This ER resident type I transmembrane protein senses luminal ER stress and transduce signals through its cytosolic RNase activity. IRE1 signaling has been shown to contribute to the progression of solid tumors through pro-angiogenic mechanisms. Herein, we expose the methodologies for investigating IRE1 signaling in tumor cells and in tumors. Moreover, we show that selective pharmacological inhibition of IRE1 RNase activity sensitizes tumor cells to ER stress.
Collapse
Affiliation(s)
- Stéphanie Lhomond
- Inserm, U1053, Université de Bordeaux, 146 rue Léo Saignat, 33000, Bordeaux, France
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Dejeans N, Pluquet O, Lhomond S, Grise F, Bouchecareilh M, Juin A, Meynard-Cadars M, Bidaud-Meynard A, Gentil C, Moreau V, Saltel F, Chevet E. Autocrine control of glioma cells adhesion/migration through Inositol Requiring enzyme 1α (IRE1α)-mediated cleavage of Secreted Protein Acidic Rich in Cysteine (SPARC) mRNA. J Cell Sci 2012; 125:4278-87. [DOI: 10.1242/jcs.099291] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The endoplasmic reticulum (ER) is an organelle specialized for the folding and assembly of secretory and transmembrane proteins. ER homeostasis is often perturbed in tumor cells due to dramatic changes in solid tumor microenvironment, thereby leading to the activation of an adaptive mechanism named the Unfolded Protein Response (UPR). The activation of the UPR sensor IRE1α has been described to play an important role in tumor progression. However, the molecular events associated with this phenotype remain poorly characterized. In the present study, we examined the effects of IRE1α signaling on glioma cells adaptation to their microenvironment. We show that the characteristics of U87 cells migration are modified under conditions where IRE1α activity is impaired (DN_IRE1). This is linked to increased stress fiber formation and enhanced RhoA activity. Gene expression profiling also revealed that loss of functional IRE1α signaling mostly resulted in the up-regulation of genes encoding extracellular matrix proteins. Among these genes, SPARC, whose mRNA is a direct target of IRE1α endoribonuclease activity, was in part responsible for the phenotypic changes associated with IRE1α inactivation. Hence, our data demonstrate that IRE1α is a key regulator of SPARC expression in vitro in a glioma model. Our results also further support the critical role of IRE1α contribution to tumor growth and infiltration/invasion and extend the paradigm of secretome control in tumor microenvironment conditioning.
Collapse
|